Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target Claudin-1 to make solid tumors vulnerable to treatment
Basel, Switzerland, December 1, 2022 – Alentis Therapeutics, the Claudin-1 company, today announced that Alberto Toso, Head of Oncology, will present a poster at the ESMO Immuno-Oncology Congress in Geneva, Switzerland (and virtually), from 7-9 December 2022.
The poster, CLAUDIN-1 Targeting Antibodies in Solid Tumors: from ALE.C04 to CLAUDIN-1 Oncology Platform, presents evidence that non-junctional Claudin-1 is overexpressed in different solid tumors, drives T-cell exclusion and resistance to checkpoint inhibitors (CPI). Importantly, the use of non-junctional Claudin-1-targeting monoclonal antibody ALE.C04 restored T-cell infiltration and CPI efficacy in a pre-clinical mouse tumor model.
ALE.C04, Alentis’ lead oncology asset, is the first potential treatment to target CLDN1 to open up the mechanical barrier that characterizes immune-excluded CLDN1+ tumors, thus making the tumors vulnerable to treatment. Based on Alentis’ pre-clinical data, rationale and safety profile, the company plans a Phase 1b trial with ALE.C04 in combination with CPIs in solid tumors, expected to initiate in the second half of 2023.
In November 2022, Alentis published pre-clinical proof-of-concept data, showing Claudin-1 monoclonal antibodies as potential first in-class compounds for HCC, in The Journal of Hepatology: https://alentis.ch/at-in-uos-published-article-in-tjoh/.
Poster presentation details are listed below:
Poster title: CLAUDIN-1 Targeting Antibodies in Solid Tumors: from ALE.C04 to CLAUDIN-1 Oncology Platform (Abstract #193P)
Presenter: Alberto Toso, Head of Oncology, Alentis Therapeutics
Authors: A. Toso 1 , G. Teixeira 1 , T. Zimmermann 1 , D. Schmitter 1 , M. Meyer 1 , M. Muller 2 , L. Mailly 2 , T. Baumert 2 , R. Iacone 1 1 Oncology, Alentis Therapeutics AG, Allschwil, Switzerland, 2 UMR_S1110, Institut de Recherche sur les Maladies Virales et Hépatiques, Strasbourg, France
Date: Thursday, 8th December 2022
Time: 12:30-13:15 CET
Location: Foyer ABC
Register to join the ESMO Immuno-Oncology Congress’ digital platform, here.
– ENDS –
About Alentis Therapeutics
Alentis Therapeutics, the Claudin-1 company, is a clinical stage biotechnology company that focuses on developing breakthrough treatments for CLDN1+ tumors and organ fibrosis.
Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting Claudin-1 (CLDN1), a previously unexploited target that plays a key role in immune-excluded tumors and in different fibrotic disease across multiple organs. Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting Claudin-1.
Alentis’ portfolio of anti-CLDN1 monoclonal antibodies includes a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is highly promising for drug development as many cancers use the TME to build barriers that shield immune system attack. Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target CLDN1 to open up the mechanical barrier that characterizes immune-excluded CLDN1+ tumors, thus making the tumors vulnerable to treatment.
In addition, Alentis’ pipeline includes a first-in-class therapy designed to modify and reverse the course of advanced organ fibrosis. ALE.F02, which is currently in Phase 1 clinical trials, is designed to target pathological overexpression of CLDN1 outside of the tight junction to resolve and reverse organ fibrosis, and is being investigated for the treatment of fibrotic disease in the kidney, liver and lung.
The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm). Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France.
For more information, visit https://alentis.ch